# Problem Statement — Clinical Trial Risk Monitor

## Background

Clinical drug trials are among the most regulated and data-intensive processes in medicine. Each trial involves hundreds of patient visits across dozens of global sites, governed by a strict **protocol** — a document specifying exactly when patients must visit, what procedures must be performed, what medications are prohibited, and what dosing schedules must be followed.

Regulatory bodies such as the **FDA**, **EMA**, and **ICH** require that every deviation from these protocols be identified, documented, classified, and remediated before trial data can be submitted for drug approval. The governing standard is **ICH E6 Good Clinical Practice (GCP)**.

---

## The Problem

Clinical trial sites generate **thousands of patient visit records** every month across 200+ sites. Compliance teams must manually cross-check each record against the protocol specification to detect:

- Visits that occurred outside the allowed time window
- Required procedures that were skipped
- Prohibited medications that were taken
- Medication adherence below the required threshold

This manual review process has three critical failure modes:

1. **It is slow** — a single trained monitor can review ~50–100 records per day. At 5,000+ records per trial, full coverage takes weeks.
2. **It is error-prone** — human reviewers miss subtle deviations, especially across large date ranges or multiple protocol versions.
3. **It is reactive** — problems are discovered during audits, *after* data integrity has already been compromised. High-risk sites are not identified until it is too late to intervene.

---

## Who is Affected

**Primary users:**
- **Clinical Research Associates (CRAs)** — monitors who visit sites and review compliance records
- **Data Managers** — responsible for clean, protocol-compliant trial data
- **Regulatory Affairs teams** — who must defend trial data integrity during FDA audits

**Secondary users:**
- **Principal Investigators** at trial sites — who need to act on CAPA (Corrective and Preventive Action) recommendations
- **Sponsor / CRO Medical Directors** — who make go/no-go decisions based on site performance

---

## Why It Matters

The cost of undetected protocol deviations is severe:

| Consequence | Real-world Impact |
|---|---|
| **Patient safety** | Missed procedures or prohibited medications can harm trial participants |
| **Data integrity** | Deviations corrupt the evidence base used to evaluate drug efficacy |
| **Regulatory failure** | FDA can reject a drug application if trial data is non-compliant |
| **Financial cost** | A single failed trial costs $10M–$100M+ and delays patient access to treatments |
| **Time cost** | Manual audits of large trials can take 3–6 months |

---

## Why Existing Solutions Fall Short

Current approaches include:

| Approach | Limitation |
|---|---|
| **Manual spreadsheet review** | Does not scale beyond ~200 records; error-prone; no risk ranking |
| **EDC system alerts** | Fires only on data entry errors, not protocol window violations |
| **Periodic site monitoring visits** | Monthly/quarterly — too infrequent to catch emerging risk trends |
| **Commercial CTMS tools** | Expensive, require months of configuration, not AI-native |

None of these approaches provide **real-time, automated, AI-accessible** deviation detection with risk-ranked site prioritization and instant CAPA generation — the three capabilities most needed by modern clinical operations teams.

---

## Our Hypothesis

If deviation detection, severity classification, and site risk scoring were **fully automated and accessible through natural language** (via IBM Bob), clinical monitors could identify at-risk sites in seconds instead of weeks — dramatically improving trial data quality and patient safety outcomes.
